Filing Flows

Filing Flows › Allogene Therapeutics (ALLO) › Who owns the stock

Who owns Allogene Therapeutics (ALLO) stock

202 funds reported Allogene Therapeutics (ALLO) shares in their latest 13F filings, worth $651M in all. The largest holder is BlackRock ($62.7M). Last quarter 108 funds added to their stakes and 86 cut them.

Largest holders of ALLO (13F)Largest holders of ALLO (13F)BlackRock$62.7MPfizer$46.9MFrazier Life Sciences Management,…$46.7MState Street$39.6MTPG GP A, LLC$38.9MSio Capital Management, LLC$27.7MPrimecap Management$27.3MVanguard Capital Management LLC$25.3MFMR LLC$25.0MCitadel Advisors LLC$21.0M

Largest holders (13F)

FundSharesValueChangeQuarter
BlackRock30,146,963$62.7Mincrease2026-06-30
Pfizer22,032,040$46.9Munchanged2026-06-30
Frazier Life Sciences Management, L.P.22,446,668$46.7Mincrease2026-06-30
State Street19,025,826$39.6Mincrease2026-06-30
TPG GP A, LLC18,716,306$38.9Munchanged2026-06-30
Sio Capital Management, LLC13,323,431$27.7Mnew2026-06-30
Primecap Management13,123,440$27.3Mincrease2026-06-30
Vanguard Capital Management LLC12,166,636$25.3Mincrease2026-06-30
FMR LLC12,009,043$25.0Mincrease2026-06-30
Citadel Advisors LLC10,087,770$21.0Mincrease2026-06-30
Two Sigma Investments, LP7,784,348$16.2Mincrease2026-06-30
Geode Capital Management, LLC7,049,328$14.7Mincrease2026-06-30
Goldman Sachs Group6,148,959$12.8Mincrease2026-06-30
Vanguard Group9,251,609$12.7Mincrease2025-12-31
GordonMD Global Investments LP5,298,000$11.0Mincrease2026-06-30

Allogene Therapeutics' latest quarter

Allogene Therapeutics, Q2 2026: revenue $4.6M, net loss $42.7M, operating cash flow −$32.0M. The chart follows the revenue to costs, profit and cash.

Questions

Who owns the most ALLO stock?

By the latest 13F filings: BlackRock ($62.7M); Pfizer ($46.9M); Frazier Life Sciences Management, L.P. ($46.7M); State Street ($39.6M); TPG GP A, LLC ($38.9M).

What is the short interest in ALLO?

53,405,256 shares were sold short at the 2026-10-15 settlement, -3.96% of the float.

Open the interactive view →

Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.